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Introduction
It is being increasingly recognized that the prevalence of vas-
cular cognitive impairment (VCI) is higher than originally 
thought. Since VCI is considered to develop under the influence 
of various cardiovascular risk factors, it is emerging as a poten-
tially treatable and preventable form of dementing disorders.
1 
However, currently available therapeutic options for treatment 
of dementia, such as cholinesterase inhibitors, were originally 
devised for Alzheimer’s disease (AD), and their application in 
vascular dementia (VaD) has produced limited and uncertain 
clinical benefit.
2
It is widely recognized that at the incipient stage, AD pa-
tients generally complain about memory problems, whereas 
VaD patients usually present with cognitive deficits involving 
nonmemory domains.
3 However, a substantial proportion of 
stroke survivors suffer from poststroke memory dysfunction, 
and several factors, including medial temporal atrophy (MTA) 
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Background and PurposezzIt was recently reported that the prevalence of poststroke memory 
dysfunction might be higher than previously thought. Stroke may exist concomitantly with under-
lying Alzheimer’s disease (AD), and so we determined whether post-stroke memory dysfunction 
indicates manifestation of underlying subclinical AD.
MethodszzOf 1201 patients in a prospective cognitive assessment database, we enrolled subjects 
with poststroke amnestic vascular cognitive impairment-no dementia (aVCIND; n=48), poststroke 
nonamnestic vascular cognitive impairment-no dementia (naVCIND; n=50), and nonstroke amnestic 
mild cognitive impairment (aMCI; n=65). All subjects had cognitive deficits, but did not meet the 
criteria for dementia. A standardized neuropsychological test battery and magnetic resonance im-
aging were performed at least 90 days after the index stroke (mean, 473 days). Visual assessment 
of medial temporal atrophy (MTA) was used as a measure of underlying AD pathology.
ResultszzThe MTA score was significantly lower in the naVCIND group (0.64±0.85, mean±SD) 
than in the aVCIND (1.10±1.08) and aMCI (1.45±1.13; p<0.01) groups. Multivariable ordinal lo-
gistic regression analysis revealed that compared with naVCIND, aVCIND [odds ratio (OR)=2.69; 
95% confidence interval (CI)=1.21-5.99] and aMCI (OR=5.20; 95% CI=2.41-11.23) were signif-
icantly associated with increasing severity of MTA.
ConclusionszzOur findings show that compared with poststroke naVCIND, the odds of having 
more-severe MTA were increased for poststroke aVCIND and nonstroke aMCI.
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or white matter hyperintensities (WMHs), are associated with 
poststroke memory dysfunction.
4 Furthermore, there is increas-
ing evidence that coexisting cerebrovascular disease precipi-
tates and unmasks underlying preclinical AD.
5 Stroke and AD 
are highly prevalent and the two conditions share common vas-
cular risk factors, and so it can be hypothesized that patients 
with poststroke memory dysfunction may have had subclini-
cal AD before their stroke, and their memory deficits may be 
the divulgence of underlying AD triggered by stroke. This is-
sue has not been studied in populations with cognitive impair-
ment-no dementia (CIND), which is clearly the foremost tar-
get of therapeutic interventions for preventing dementia.
6 We 
sought to test this hypothesis by measuring the severity of 
MTA, which is an acknowledged neuroimaging index of AD.
7 
For this purpose, we compared patients with poststroke amnes-
tic vascular cognitive impairment-no dementia (aVCIND) and 
patients with nonstroke amnestic mild cognitive impairment 
(aMCI) to patients with poststroke nonamnestic vascular cog-
nitive impairment-no dementia (naVCIND).
       
Methods
Subject recruitment
This was a retrospective analysis based on a prospective cog-
nitive test database. The patient selection process is summa-
rized in Fig. 1. A battery of standard neuropsychological tests 
was administered to 1201 patients at Seoul National Universi-
ty Bundang Hospital between May 2007 and March 2009. Of 
these 1201 patients, 396 had a documented history of clinical 
stroke with which neuroimaging findings were compatible; the 
remaining 805 patients were designated as nonstroke subjects. 
Stroke was defined using the World Health Organization def-
inition of “rapidly developed clinical signs of focal or global 
disturbance of cerebral function, lasting more than 24 hours 
or leading to death, with no apparent cause other than a vascu-
lar origin”.
8 CIND was defined as having cognitive impairment 
but not meeting the Diagnostic and Statistical Manual of Men-
tal Disorders, Fourth Edition, Text Revision (DSM-IV-TR) cri-
teria for dementia.
6,9 We also applied an Instrumental Activity 
of Daily Living score of <0.43 as indicating “no dementia”.
10
For poststroke patients, a standardized neuropsychological 
battery was administered at least 90 days after stroke onset. 
The interval from stroke onset to neuropsychological evalua-
tion was 473±311 days (mean±SD). We selected poststroke 
VCIND patients (n=156) who had an impairment in one or more 
cognitive domains but did not meet the DSM-IV-TR criteria 
for dementia. Cognitive impairment in language, visuospatial 
function, or memory domains was defined as a score in the 
each of the domain-specific tests of less than the 7th percen-
tile (mean-1.5 SD). Cognitive impairment in the frontal do-
main was determined by a score of less than the 7th percentile 
in two or more of the five frontal-domain-specific tests (details 
of the neuropsychological tests used are given below). Post-
stroke VCIND was further classified into poststroke amnestic 
VCIND (aVCIND; n=71) and poststroke nonamnestic VCIND 
(naVCIND; n=85), according to the presence of memory im-
pairment. Among 805 nonstroke patients, 331 were identified 
as having CIND; 128 patients who had cognitive impairment 
in the memory domain were further categorized into the aMCI 
group. Patients without coronal magnetic resonance imaging 
(MRI) results were excluded (23 from the aVCIND group, 35 
from the naVCIND group, and 63 from the aMCI group). These 
criteria resulted in 163 patients (48 aVCIND, 50 naVCIND, 
and 65 aMCI) being included in this study. All of the included 
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Normal cognition 
no dementia
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Normal cognition 
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Fig. 1. Recruitment of the study popula-
tion. Gray boxes denote the enrolled sub-
jects who were included in the final anal-
yses. aVCIND: amnestic vascular co-
gnitive impairment-no dementia, na-
VCIND: nonamnestic vascular cognitive 
impairment-no dementia, aMCI: am-
nestic mild cognitive impairment.Kim BJ et al.
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patients were free of any other organic medical or neurologi-
cal conditions that may adversely affect cognitive functions. 
The study protocols were approved by the local institutional 
review board.
       
Cognitive assessment
A battery of standard neuropsychological tests was adapted 
from the 60-minute neuropsychology protocol of the Vascu-
lar Cognitive Impairment Harmonization Standards (VCI-
HS).
11 The Korean-VCIHS Neuropsychologic Battery was 
standardized for the Korean population, and its validity and 
feasibility were examined and confirmed in a multicenter epi-
demiological study involving 15 hospitals with nationwide 
coverage.
12 The Korean-VCIHS Neuropsychologic Battery 
comprises the following cognitive tests of various cognitive 
domains: frontal executive/activation (animal naming test, 
phonemic fluency test, Digit Symbol Coding, Trail Making 
Test), language/lexical retrieval (Korean-Boston Naming Test 
- short form), visuospatial (Rey-Osterrieth Complex Figure 
Test: Copy), memory (Seoul Verbal Learning Test), depressive 
mood (Geriatric Depression Scale), and others (Informant 
Questionnaire for Cognitive Decline in the Elderly, Korean 
Mini Mental State Examination, and Instrumental Activity of 
Daily Living). Trained clinical psychometricians who were 
blinded to the clinical and radiological profile of each patient 
administered the battery. The score on each cognitive test was 
transformed into a standardized Z-score [Z-score=(individual 
score - population mean score)/(population SD)].
       
Vascular risk factors and 
MRI evaluation of the patients
The baseline demographic and clinical characteristics of pa-
tients included in the study were collected, including age, gen-
der, years of education, handedness, and vascular risk factors, 
such as presence of hypertension (previous use of antihyper-
tensive medication, systolic blood pressure >140 mm Hg, or 
diastolic blood pressure >90 mm Hg), diabetes mellitus (pre-
vious use of glucose-lowering medication, fasting blood glu-
cose >7.0 mmol/L, or 2-hours-postprandial blood glucose 
>11.1 mmol/L), dyslipidemia (previous use of lipid-lowering 
medication, total cholesterol >6.0 mmol/L, or low-density li-
poprotein cholesterol >4.14 mmol/L), and smoking (current 
smoker or stopped smoking within the past 5 years). For post-
stroke patients, the severity of stroke was assessed using the 
National Institutes of Health Stroke Scale score, which was 
measured at hospital admission for the most-recent stroke, 
and the modified Rankin Scale score, measured at discharge 
from that admission.
All participants underwent brain MRI, and the mean inter-
val between MRI and test for the neuropsychological battery 
was 153 days. The MRI studies were performed using a 1.5-tes-
la superconducting magnet (Intera, Philips Healthcare, Eind-
hoven, The Netherlands). The standardized MRI protocols 
consisted of an axial T2-weighted spin echo, coronal T2-
weighted spin echo, fluid-attenuated inversion recovery im-
age, gradient-echo image, and axial T1-weighted image. MTA 
was rated using a 5-point rating scale, as described previously.
13 
Both sides were rated simultaneously, and in the case of notice-
able asymmetry, the score of the more affected side was chosen 
as being representative.
14 WMHs were rated visually using a 
10-point rating scale, based on the fluid-attenuated inversion 
recovery image.
15 Information regarding the subtype, location, 
and laterality of the stroke and the involvement of the medial 
temporal lobe was obtained from the prospective stroke regis-
try and by reviewing the electronic medical records and MRI 
findings. Two reviewers (B.J. Kim and M.-Y. Oh) indepen-
dently and blindly rated the MTA and WMHs (Spearman’s 
correlation coefficient: 0.79 for MTA and 0.73 for WMHs), 
and any disagreement was settled by consensus.
       
Statistical analysis
Differences in baseline characteristic variables among the 
poststroke aVCIND, poststroke naVCIND, and aMCI groups 
were examined by using Pearson’s χ
2 test, the Kruskal-Wallis 
test with pairwise Mann-Whitney U test, or one-way analysis 
of variance with Bonferroni’s post-hoc adjustment for multiple 
comparisons, as appropriate. Z-scores were described as mean 
±SE values. Bivariate analyses and multivariable ordinal lo-
gistic regression analyses performed by taking the MTA score 
as a dependent variable were used to assess whether covariates 
were associated with an increasing severity of MTA. To build 
ordinal logistic regression models, three patients with the 
most-severe MTA (MTA score=4) were combined with the 
group of patients with an MTA score of 3. The distribution of 
patients by MTA score used in the model was as follows: 60 
(36.8%), 52 (31.9%), 29 (18.0%), and 22 (13.5%) patients with 
MTA scores of 0, 1, 2, and 3 or 4, respectively. The propor-
tional odds assumption for each ordinal logistic regression 
model was examined and found to be satisfactory. Variables 
with a bivariate p<0.10 for their association with MTA were 
selected for adjustment in multivariate models, including age, 
WMHs, hypertension, and diabetes. Statistical significance was 
defined as a probability value of p≤0.05. All statistical analy-
ses were performed using SPSS 15.0 (SPSS, Chicago, IL, USA).
Results
The distributions of gender and MTA differed significantly 
among the three CIND groups; however, age, dominant hand, 
education, WMHs, and cardiovascular risk factors did not dif-MTA and Post-Stroke Memory Dysfunction 
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fer (Table 1). Stroke-related features, the location and laterali-
ty of stroke lesions, the stroke subtype, and the severity of the 
stroke did not differ significantly between poststroke aVCIND 
and naVCIND patients. The MTA score varied significantly 
among the three types of CIND (p<0.01, Kruskal-Wallis test). 
Pairwise comparisons revealed that the MTA score was signif-
icantly lower in the poststroke naVCIND group (median, in-
terquartile range; 1, 0-2) than in the poststroke aVCIND group 
(1, 0-1; p=0.022) and the aMCI group (1, 0-2; p<0.01; the sig-
nificance level was set to p≤0.017 after adjusting for pairwise 
comparison). However, the MTA score did not differ between 
the poststroke aVCIND and aMCI groups (p=0.10).
Analysis of variance showed that with the exception of the 
memory score, the domain-specific test scores did not differ 
among the three CIND groups (Table 2) (Fig. 2). The memory 
domain was used to differentiate poststroke aVCIND from 
poststroke naVCIND. Global Frontal Function score, obtained 
by averaging the Z-scores of the five frontal domain-specific 
tests, did not differ between the groups (p=0.94).
Ordinal logistic regression analyses showed that there was a 
significant association between the severity of MTA and the 
type of CIND (Table 3). In multivariable analysis, the odds ra-
tio for poststroke aVCIND was 2.69 (95% confidence inter-
val=1.21-5.99) and the odds ratio for aMCI was 5.20 (95% con-
Table 1. Comparison of baseline characteristics among the three CIND groups
Poststroke aVCIND (n=48) Poststroke naVCIND (n=50) aMCI (n=65) p*
Demographic factors
Male gender 39 (81.3%) 27 (54.0%) 45 (69.2%) 0.02
Age (years) 66.31±9.99 67.64±9.70 66.63±7.94 0.75
Right-handedness 44 (91.7%) 48 (96.0%) 61 (93.8%) 0.87
Years of education 0.07
0-6 years 11 (22.9%) 18 (36.0%) 12 (18.5%)
7-12 years 25 (52.1%) 16 (32.0%) 38 (58.5%)
>13 years 12 (25.0%) 16 (32.0%) 15 (23.1%)
Cardiovascular risk factors
Hypertension 32 (66.7%) 32 (64.0%) 47 (72.3%) 0.62
Diabetes 19 (39.6%) 14 (28.0%) 19 (29.2%) 0.39
Hyperlipidemia 24 (50.0%) 20 (40.0%) 22 (33.8%) 0.22
Smoking 24 (50.0%) 22 (44.0%) 37 (56.9%) 0.39
Neuroimaging factors
WMHs, mean±SD 2.52±1.44 2.52±2.17 3.06±2.10 0.23
MTA score
0 17 (35.4%) 27 (54.0%) 16 (24.6%)
1 16 (33.3%) 17 (34.0%) 19 (29.2%)
2 9 (18.8%) 3 (6.0%) 17 (26.2%)
3 5 (10.4%) 3 (6.0%) 11 (16.9%)
4 1 (2.1%) 0 (0%) 2 (3.1%)
Median (IQR) 1 (0, 2) 0 (0, 1) 1 (0, 2) <0.01
Stroke-related factors
Ischemic stroke 42 (87.5%) 48 (96.0%) - 0.16
Supratentorial stroke 43 (89.6%) 47 (94.0%) - 0.48
Laterality of stroke 0.36
Left 29 (60.4%) 28 (56.0%) -
Right 13 (27.1%) 19 (38.0%) -
Bilateral 6 (12.5%) 3 (6.0%) -
Involvement of medial temporal lobe 3 (6.3%) 2 (4.0%) - 0.67
Admission NIHSS score, median (IQR) 2 (1, 4) 2 (1, 6) - 0.91
Discharge mRS score, median (IQR) 1 (1, 2) 1 (0, 3) - 0.82
Values are number of patients (percentages) except where indicated otherwise. 
*Pearson’s Chi-squared test, analysis of variance (ANOVA), Kruskal-Wallis test, or Mann-Whitney’s U test, as appropriate.
WMHs: white-matter hyperintensities, CIND: cognitive impairment-no dementia, aVCIND: amnestic vascular cognitive impairment 
and no dementia, naVCIND: nonamnestic vascular cognitive impairment-no dementia, aMCI: amnestic mild cognitive impairment, 
MTA: medial temporal atrophy, NIHSS: National Institutes of Health Stroke Scale, IQR: interquartile range, mRS: modified Rankin Scale.Kim BJ et al.
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fidence interval=2.41-11.23) relative to poststroke naVCIND. 
When compared with aMCI, poststroke aVCIND was not 
significantly associated with the severity of MTA (p=0.11). In 
addition, age and diabetes mellitus were independently associ-
ated with increasing severity of MTA (Table 3).
       
Table 2. Comparison of cognitive function and other related tests among the three CIND groups
Poststroke aVCIND (n=48) Poststroke naVCIND (n=50) aMCI (n=65) p*
Frontal executive and association function
Animal naming, Z-score -0.92±0.15 -0.67±0.14 -0.84±0.15 0.51
COWAT, phonemic, Z-score -0.57±0.17 -0.48±0.17 -0.69±0.16 0.66
Digit symbol coding, Z-score -0.97±0.17 -0.73±0.16 -0.87±0.13 0.55
Trail making test - A, Z-score -0.90±0.19 -1.87±0.48 -1.38±0.26 0.14
Trail making test - B, Z-score -1.55±0.36 -0.66±0.30 -0.83±0.20 0.08
Global frontal function, Z-score -0.99±0.15 -0.91±0.15 -0.96±0.13 0.94
Language/lexical retrieval
Boston naming test, Z-score -0.82±0.28 -0.68±0.26 -1.12±0.20 0.41
Visuospatial function
RCFT score, Z-score -1.36±0.24 -1.34±0.26 -1.41±0.19 0.97
Memory function
HVLT-R, delayed recall, Z-score  -2.31±0.13
† -0.23±0.11  -2.28±0.11
† <0.01
Global cognitive function
MMSE, raw score  25.02±0.41 25.70±0.52 24.88±0.49 0.45
MMSE, Z-score -0.74±0.14 -0.28±0.12 -0.70±0.16 0.06
Other functional assessments
IADL, raw score  0.12±0.02 0.09±0.01  0.13±0.02 0.24
IQCODE, raw score  3.36±0.04 3.40±0.05  3.40±0.03 0.78
Geriatric Depression Scale, raw score 11.81±1.10 12.26±1.01 13.45±0.82 0.44
Each score is the mean±SE value. 
*ANOVA, 
†Significant difference from poststroke naVCIND in multiple comparisons with Bonferroni’s post-hoc adjustment.
aMCI: amnestic mild cognitive impairment, aVCIND: amnestic vascular cognitive impairment and no dementia, naVCIND: nonam-
nestic vascular cognitive impairment-no dementia, CIND: cognitive impairment-no dementia, COWAT: Controlled Oral Word Associ-
ation Test, HVLT-R: Hopkins Verbal Learning Test-Revised, IADL: Instrumental Activity of Daily Living, IQCODE: Informant Questionnaire 
for Cognitive Decline in the Elderly, MMSE: Mini-Mental Status Examination, RCFT: Rey-Osterrieth Complex Figure Test.
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Fig. 2. Comparison of Z-scores among 
the three vascular cognitive impairment 
and no dementia (CIND) groups. aMCI: 
amnestic mild cognitive impairment, 
aVCIND: amnestic vascular cognitive 
impairment-no dementia, naVCIND: non-
amnestic vascular cognitive impairment-
no dementia.MTA and Post-Stroke Memory Dysfunction 
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Discussion
The patients in this study were divided into two groups accord-
ing to the presence of memory dysfunction so as to make it 
possible to evaluate the association between MTA and memo-
ry dysfunction in patients with poststroke CIND. The effect of 
stroke was evaluated by comparing nonstroke aMCI patients 
with poststroke CIND patients. With the exception of memory, 
patients in the three CIND groups defined in our study had 
similar cognition and functional ability profiles. We found that 
the odds of having more-severe MTA were increased for 
poststroke aVCIND and nonstroke aMCI relative to poststroke 
naVCIND. Older age and diabetes mellitus were also found 
to be independently associated with MTA.
The concept of poststroke memory dysfunction seems coun-
terintuitive in that stroke does not usually affect the memory-
processing structures.
16 However, one-third to one-half of 
stroke survivors were reported to have memory dysfunction 
around 3 months after the stroke,
4 and the risk of dementia 
doubles with a history of stroke.
17 Both MTA and imaging 
markers of cerebrovascular disease are useful in predicting the 
development of clinical dementia.
18 Experimental studies have 
also suggested that certain mechanisms are responsible for pro-
gressive memory deterioration. Decreased cerebral blood 
flow, which occurs with ischemic stroke, may modulate traf-
ficking of β-amyloid between the blood and the brain, result-
ing in the attenuation of β-amyloid clearance from the brain.
19,20 
Moreover, small ischemic injuries that develop in the paraven-
Table 3. Results from univariate and multivariate ordinal logistic regression analyses for the increasing severity of MTA
Univariate OR (95% CI) Multivariable OR
† (95% CI)
Demographic factors
Male gender 0.99 (0.55-1.80) -
Age (per 1-year increase) 1.09 (1.05-1.13) 1.10 (1.06-1.14)
Right-handedness 0.77 (0.24-2.43) -
Years of education
0-6 years 01.00 (reference) -
7-12 years 1.25 (0.57-2.73)
>13 years 1.22 (0.61-2.42)
Neuroimaging factors
Types of CIND
Poststroke aVCIND 2.35 (1.11-4.96) 2.69 (1.21-5.99)
aMCI 4.23 (2.08-8.63) 05.20 (2.41-11.23)
Poststroke naVCIND 01.00 (reference) 01.00 (reference)
WMHs (0-9 scale) (per 1-grade increase) 1.33 (1.15-1.55) 1.14 (0.96-1.34)
Cardiovascular risk factors
Hypertension 2.02 (1.09-3.74) 1.69 (0.85-3.34)
Diabetes 2.48 (1.35-4.56) 2.01 (1.05-3.86)
Hyperlipidemia 0.93 (0.53-1.64) -
Smoking 1.15 (0.66-2.02) -
Stroke-related factors*
Ischemic stroke 1.67 (0.41-6.80) -
Supratentorial stroke 0.61 (0.16-2.29) -
Location of stroke
Left 0.77 (0.34-1.71) -
Bilateral 1.21 (0.31-4.70) -
Right 01.00 (reference)
Stroke involving medial temporal lobe 02.44 (0.48-12.45) -
Admission NIHSS score (per 1-point increase) 1.03 (0.92-1.15) -
Discharge mRS score (per 1-point increase) 1.16 (0.87-1.56) -
Univariate or multivariable ordinal logistic regression analyses were performed by taking the MTA score as a dependent variable.
*Univariate ORs of stroke-related factors were calculated based on patients with poststroke aVCIND and naVCIND, excluding the 
nonstroke aMCI group, 
†A multivariable model was constructed using variables with p<0.10 in univariate analyses.
aMCI: amnestic mild cognitive impairment, aVCIND: amnestic vascular cognitive impairment-no dementia, CI: confidence interval, 
CIND: cognitive impairment-no dementia, MTA: medial temporal atrophy, naVCIND: nonamnestic vascular cognitive impairment-no 
dementia, OR: odds ratio, WMHs: white-matter hyperintensities.Kim BJ et al.
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tricular area and deep structures may cause widespread dis-
connection of cholinergic innervations to the cortex,
21,22 there-
by inducing additive attrition of cognitive reserve.
23
We deliberately recruited CIND patients from our large 
population of patients with neuropsychological assessments. 
Cholinesterase inhibitors and memantine, which are used to 
treat AD patients, seem to provide little benefit to VaD patients,
2 
and there has been no clinical trial regarding their efficacy in 
the treatment of poststroke dementia. According to DSM-IV-
TR criteria, the presence of stroke per se in a demented indi-
vidual excludes a diagnosis of AD. However, our results, as 
well as those from other recent studies, show that VaD patients 
usually have “mixed” pathology.
24,25 In this context, our find-
ings suggests that poststroke CIND can be regarded as subclin-
ical AD if there is MTA or memory dysfunction, and that cho-
linesterase inhibitors or memantine can be beneficial for these 
individuals. In addition, the consideration of MTA when recruit-
ing subjects for VCI trials or in secondary analysis of VCIND 
research would improve the homogeneity of study populations.
The association between MTA and poststroke dementia has 
been addressed by previous studies. However, the clinical im-
plications of the results obtained in those studies were limited 
because they disregarded CIND or were case series of stroke 
at a specific location.
26-29 In addition to the type of CIND, our 
study detected increases in the severity of MTA with the pres-
ence of diabetes, which is consistent with a previous report.
30 
WMHs and hypertension were not associated with severity of 
MTA in multivariable analyses, in spite of their significance in 
univariate analyses (Table 3). A lack of power due to the small 
sample is a possible explanation for this finding. Furthermore, 
previous studies also found that the association between 
WMHs and MTA is controversial.
31,32 Contrary to the concept 
of early executive dysfunction in VaD, frontal function did not 
differ among the three CIND groups in the present study. How-
ever, the development of executive dysfunction has been re-
ported to be as common in AD as in VaD.
33
There are several reasons why our results should be inter-
preted with caution. First, this study was conducted at a single 
center, had a cross-sectional design, and a relatively small sam-
ple. Second, it should be noted that approximately 5% of MCI 
patients are reported to return to normal over time and that the 
natural course of progressive memory deterioration is thought 
to be dynamic.
4,34 Third, single- and multidomain CINDs were 
not distinguished in our study due to the small sample. Fourth, 
the visual rating scale of MTA was used instead of a volumet-
ric assessment. However, volumetry is cumbersome because 
it requires expensive software and a time-consuming render-
ing process, which limits its usefulness for research purposes. 
Moreover, it has been reported that visual and volumetric as-
sessments of MTA are equally accurate.
35,36 Fifth, prestrike 
neuropsychological assessments were not available for our 
subjects.
Our results do not indicate that poststroke memory dysfunc-
tion is essentially AD or that such patients should receive cho-
linesterase inhibitors - only a prospective cohort study with 
an adequate duration of follow-up can clarify the association 
between AD and poststroke memory dysfunction. Consider-
ing the increasing burden of stroke and dynamic interrelation-
ships among vascular etiologies, degenerative changes in the 
brain, and host factors with respect to VCI,
37,38 our findings 
support the notion that a stroke event may trigger subclinical 
AD-type neurodegeneration and result in poststroke memory 
dysfunction.
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